Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.43

Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMRGet Free Report) have earned an average rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. Nine research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $20.43.

LRMR has been the topic of several recent analyst reports. Oppenheimer started coverage on Larimar Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $26.00 price target on the stock. Robert W. Baird assumed coverage on Larimar Therapeutics in a research note on Wednesday, September 4th. They set an “outperform” rating and a $16.00 target price for the company. Wedbush initiated coverage on shares of Larimar Therapeutics in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $22.00 price target on the stock. Baird R W upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 4th. Finally, HC Wainwright initiated coverage on shares of Larimar Therapeutics in a research report on Wednesday, October 2nd. They issued a “buy” rating and a $15.00 target price on the stock.

View Our Latest Stock Report on Larimar Therapeutics

Hedge Funds Weigh In On Larimar Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LRMR. Quarry LP increased its stake in shares of Larimar Therapeutics by 966.7% in the second quarter. Quarry LP now owns 8,000 shares of the company’s stock valued at $58,000 after buying an additional 7,250 shares during the period. Thoroughbred Financial Services LLC acquired a new stake in Larimar Therapeutics during the 2nd quarter valued at approximately $94,000. SG Americas Securities LLC bought a new position in Larimar Therapeutics during the 3rd quarter worth approximately $94,000. EntryPoint Capital LLC acquired a new position in shares of Larimar Therapeutics in the 1st quarter worth approximately $106,000. Finally, AQR Capital Management LLC bought a new stake in shares of Larimar Therapeutics in the 2nd quarter valued at $113,000. 91.92% of the stock is currently owned by institutional investors and hedge funds.

Larimar Therapeutics Stock Up 0.6 %

LRMR opened at $8.01 on Thursday. The stock has a market capitalization of $511.05 million, a price-to-earnings ratio of -8.26 and a beta of 0.98. Larimar Therapeutics has a twelve month low of $2.18 and a twelve month high of $13.68. The company has a 50-day simple moving average of $7.32 and a 200 day simple moving average of $7.78.

Larimar Therapeutics (NASDAQ:LRMRGet Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.02). Sell-side analysts anticipate that Larimar Therapeutics will post -1.38 EPS for the current fiscal year.

Larimar Therapeutics Company Profile

(Get Free Report

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

Featured Articles

Analyst Recommendations for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.